The use of anti-interleukin-1 agents and tumor necrosis factor‐alpha inhibitors in renal transplant recipients

Abstract

Objectives: The aim of this study was to investigate the efficacy and safety of anti-interleukin-1 (anti-IL-1) agents and tumor necrosis factor‐alpha(TNF-α) inhibitors in renal transplant patients. Patients and methods: Between February 2014 and February 2020, data of 12 renal transplant recipients (9 males, 3 females; median age: 51 years;range, 19 to 70 years) who received anti-IL-1 agents or TNF-α inhibitors for inflammatory diseases in the post-transplant time period and werefollowed in a single transplant center (n=12) were retrospectively analyzed. A total of 46 cases were reported in the literature, before the data werecollected. The overall outcomes of all cases were analyzed in this study. Results: Thirty-seven patients received anti-IL-1 agents in the post-transplant period. The main indications for anti-IL-1 agents were familialMediterranean fever (FMF) and amyloidosis (75.7%). The continuation rate of colchicine treatment in patients with FMF was 85.7%. Anti-IL-1 agentsprevented attacks completely in 89.3% of FMF patients. The number of cases used TNF-α inhibitors among renal transplant patients was lower (n=21).The TNF-α inhibitors were used mainly for inflammatory bowel diseases (57.1%) and ankylosing spondylitis (33.3%) and suppressed the diseaseactivity in most of the patients with inflammatory diseases (72.7%). Death (n=3) and malignancies (n=3) were reported in patients who receivedTNF-α inhibitors, but not in patients who received anti-IL-1. The renal outcomes and graft survival rates were satisfactory in patients who receivedboth anti-IL-1 agents and TNF-α inhibitors. Conclusion: Our results support that anti-IL-1 agents can be used effectively and safely in renal transplant patients.